Massachusetts Institute of Technology’s Ocular Therapeutix OCUL Stock Holding History

Massachusetts Institute of Technology’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$1.04M	Buy	+50,396	New	+$748K	1.17%	5

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Massachusetts Institute of Technology's OCUL Position: Q4 2020 in Review

Massachusetts Institute of Technology opened a new position in Ocular Therapeutix (OCUL) in Q4 2020: 50,396 shares worth $1.04M. The stake represents 1.17% of the portfolio and ranks #5 among its holdings.

149 funds tracked by Wall St. Rank hold OCUL as of Q4 2020.

Massachusetts Institute of Technology held 50,396 shares of Ocular Therapeutix worth $1.04M as of Q4 2020.
Ocular Therapeutix was a new Massachusetts Institute of Technology position in Q4 2020.
Ocular Therapeutix made up 1.17% of Massachusetts Institute of Technology's portfolio in Q4 2020, its #5 holding.
149 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2020.

Based on Massachusetts Institute of Technology's 13F filing for Q4 2020, filed 5 Feb 2021.